Maine Patent of the Month – March 2023

RxAnte Inc is a healthcare technology company that has developed an innovative system for predicting medication adherence. By providing health plans and providers with actionable insights, strategies, and a portfolio of interventions, RxAnte helps make medications work better for everyone.

In order to support this mission, the company has developed the technology needed to support their predictive analytics. In line with this, the company has patented their system for calculating the value of future adherence (VFA). The healthcare profession is rapidly changing. We now live in a time where health care has become a daily discussion for most media outlets. It is now more important than ever for health care providers, health insurance companies, and health care facilities to understand the costs associated with each patient and the patient’s adherence (or non-adherence) to a treatment program. 

Calculating the VFA metric provides healthcare providers with insight into the probability related to a patient’s adherence and the potential cost reduction associated with becoming adherent.

The system generates a list of candidates using medical history data. The system then calculates one or more values associated with medication adherence for each candidate in the list. To calculate the values, the system uses several methods, including determining a probability of non-adherence related to one or more therapies, determining a probability of conversion from non-adherence to adherence, and determining a cost reduction related to the therapies. The system then calculates a score for each candidate by combining the probabilities and cost reduction for each therapy and further combining the calculated score for each therapy for each candidate to create a total score.

RxAnte’s system uses statistical methods to calculate the total score, and it includes separate monetary costs associated with future adherence for each therapy. The system also displays a listing of each candidate and a value associated with the total score, corresponding to possible future adherence to a treatment for each candidate.

The system is particularly useful in identifying patients who are at risk of non-adherence and can help healthcare professionals intervene early to improve patient outcomes. The system can also be used to determine the value of future adherence, making it a valuable tool for healthcare providers and payers alike.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts